Verona: Hospital pharmacists learned a hard lesson across several winters of antibiotic and painkiller shortages. The cheapest tender wins the contract, the cheapest supplier concentrates production in one plant on one continent, and the plant goes down. Europe’s answer, the Critical Medicines Act, tries to write that lesson into procurement law.
Parliament and Council negotiators reached a provisional agreement on 12 May 2026. The text still needs formal ratification by both institutions, and lawyers expect publication in the Official Journal toward the end of this year, at which point the application dates become firm. The Council set out the shape of the deal in its May statement.
The instrument does three things. It requires public buyers of critical medicines to apply supply chain resilience requirements, weighing criteria that have nothing to do with price. Stock obligations count. So does diversification of supply sources, and whether a supplier lets buyers monitor its chain. It also makes it easier for member states to procure jointly, and it channels support toward manufacturing capacity for critical medicines and their active ingredients inside the Union.
Generic manufacturers have argued for years that European procurement eroded its own supplier base. Contracts awarded on price alone drove margins on old off-patent molecules to nothing, factories closed, and production consolidated in a handful of sites in India and China. Nobody planned that outcome. Tender rules produced it one award at a time, and no single buyer had an incentive to pay more for redundancy that benefited everyone.
Resilience is not free, and the Act does not pretend otherwise. Health ministries operating under fiscal rules will pay more per pack for the same molecule, and they will have to defend that in national budgets where the shortage they avoided never appears as a line item. Smaller member states worry about a different problem. Joint procurement helps them only if the larger buyers actually join, rather than running national tenders that get served first.
The Act also sits alongside the broader pharmaceutical package, which carries its own shortage and supply provisions and has moved through the institutions on a separate track. Companies now face two overlapping frameworks and have asked the Commission to explain which obligation governs where they conflict. The Commission’s own page treats the two as complementary, which is a policy statement rather than a legal answer.
The measure of success is unglamorous and slow. It is whether a European plant that makes a cheap sterile injectable can still cover its costs in 2031, because a procurement officer somewhere had to value the fact that it exists. Shortages will not disappear. What can change is whether Europe keeps the capacity to respond to them.
